Jade Biosciences (JBIO) H.C. Wainwright 28th Annual Global Investment Conference summary

Strategic overview and pipeline focus

• Focused on developing best-in-class therapeutics for autoimmune diseases, leveraging high-affinity antibodies and half-life extension technology from Paragon.

• Lead asset JADE101 targets IgA nephropathy, with positive phase I data showing deep, sustained IgA reductions and a Q12-week dosing interval.

• Pipeline includes JADE201 (anti-BAFF receptor, phase I in RA) and JADE301 (anti-interferon beta for dermatomyositis), both aiming for differentiated efficacy and convenient dosing.

• Team has significant experience from Chinook, particularly in IgA nephropathy drug development.

• Strong financial position with $461 million in cash, supporting development through Q4 2028.

Clinical data and development plans

• JADE101 phase I showed up to 70% IgA reduction at induction dose, with sustained effect at Q12-week maintenance dosing.

• Phase II for JADE101 is a 30-patient open-label study, with data expected in 2027; phase III initiation planned for first half of 2027.

• Phase III will include both Q8-week and Q12-week dosing arms to address regulatory expectations and ensure robust safety data.

• JADE201 phase I in RA will inform indication selection, focusing on receptor occupancy and duration of action for optimal efficacy.

• JADE301 preclinical data to be presented at EADV, comparing binding affinity and half-life to dazukibart in non-human primates.

Market landscape and differentiation

• IgA nephropathy seen as a large, high-risk market with significant unmet need; anti-APRIL mechanism expected to become foundational therapy.

• JADE101 designed for high potency and long-acting effect, aiming for best-in-class efficacy and low treatment burden for young patients.

• Competitor data reviewed, with JADE101 showing deeper IgA reductions than first-generation anti-APRILs and a favorable safety profile.

• Regulatory environment evolving, with FDA and stakeholders supporting shorter placebo-controlled periods in phase III trials.

• Capital allocation strategy balances ambitious development with focus on key indications for each asset.